We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shire Gets FDA Nod for Cinryze Tech Transfer to New Site
Read MoreHide Full Article
Shire plc announced that it has received an FDA approval for transferring the product manufacturing technology of its hereditary angioedema (HAE) drug, Cinryze (C1 esterase inhibitor), to its in-house manufacturing site in Vienna, Austria. The company expects to start commercial manufacturing of Cinryze at the given site during the first quarter of 2018.
Notably, the company has been facing consistent supply challenges for Cinryze, which is produced by a single third-party supplier.
In third-quarter 2017, the company’s Genetic disease portfolio sales were down 7.1% to $628.1 million, primarily due to lower sales of Cinryze, having plunged 65.6% to $56.9 million as a result of supply shortage arising from manufacturing interruption.
With the FDA’s approval of the tech transfer, the company will be able to address the supply disruption of Cinryze as demand for the drug has periodically exceeded its supply from the company’s single third-party partner.
Shire’s shares have underperformed the industry in a year’s time. The stock has lost 13.2%, comparing unfavorably with the industry’s rally of 16.1%.
We remind investors that Cinryze is approved for the treatment and pre-procedure prevention of angioedema attacks in children (aged two years and above) with HAE.
It is important to mention that Shire acquired ViroPharma in 2014, which added Cinryze to its portfolio. The drug complements Shire's Firazyr, indicated for the on-demand treatment of acute HAE attacks. The buyout of Dyax also added Kalbitor to Shire’s HAE portfolio.
Shire has a dominant position in the rare diseases market, growing faster than the broader biopharmaceutical market. A strong performance of Vyvanse, Lialda and Firazyr should continue to drive its top line in the upcoming quarters. The approval of Xiidra has also boosted the company’s revenues.
Exelixis’ earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days. The company pulled off a positive earnings surprise in each of the trailing four quarters with an average beat of 572.92%. Share price of the company has soared 52.1% in a year’s time.
XOMA’s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days. The company came up with an average beat of 47.92%. The stock has skyrocketed 601.4% in the last 12 months.
Sucampo’s earnings per share estimates have moved north from $1.15 to $1.19 for 2018 in the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.63%. The company’s share price has surged 52.5% in a year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Shire Gets FDA Nod for Cinryze Tech Transfer to New Site
Shire plc announced that it has received an FDA approval for transferring the product manufacturing technology of its hereditary angioedema (HAE) drug, Cinryze (C1 esterase inhibitor), to its in-house manufacturing site in Vienna, Austria. The company expects to start commercial manufacturing of Cinryze at the given site during the first quarter of 2018.
Notably, the company has been facing consistent supply challenges for Cinryze, which is produced by a single third-party supplier.
In third-quarter 2017, the company’s Genetic disease portfolio sales were down 7.1% to $628.1 million, primarily due to lower sales of Cinryze, having plunged 65.6% to $56.9 million as a result of supply shortage arising from manufacturing interruption.
With the FDA’s approval of the tech transfer, the company will be able to address the supply disruption of Cinryze as demand for the drug has periodically exceeded its supply from the company’s single third-party partner.
Shire’s shares have underperformed the industry in a year’s time. The stock has lost 13.2%, comparing unfavorably with the industry’s rally of 16.1%.
We remind investors that Cinryze is approved for the treatment and pre-procedure prevention of angioedema attacks in children (aged two years and above) with HAE.
It is important to mention that Shire acquired ViroPharma in 2014, which added Cinryze to its portfolio. The drug complements Shire's Firazyr, indicated for the on-demand treatment of acute HAE attacks. The buyout of Dyax also added Kalbitor to Shire’s HAE portfolio.
Shire has a dominant position in the rare diseases market, growing faster than the broader biopharmaceutical market. A strong performance of Vyvanse, Lialda and Firazyr should continue to drive its top line in the upcoming quarters. The approval of Xiidra has also boosted the company’s revenues.
Zacks Rank & Key Picks
Shire carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the health care sector are Exelixis, Inc. (EXEL - Free Report) , XOMA Corporation (XOMA - Free Report) and Sucampo Pharmaceuticals, Inc. . While Exelixis and XOMA sport a Zacks Rank #1 (Strong Buy), Sucampo carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis’ earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days. The company pulled off a positive earnings surprise in each of the trailing four quarters with an average beat of 572.92%. Share price of the company has soared 52.1% in a year’s time.
XOMA’s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days. The company came up with an average beat of 47.92%. The stock has skyrocketed 601.4% in the last 12 months.
Sucampo’s earnings per share estimates have moved north from $1.15 to $1.19 for 2018 in the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.63%. The company’s share price has surged 52.5% in a year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>